FBXO32 and obesity disorder: The atrogene F-box protein 32 (Fbxo32), known to be transcriptionally increased in skeletal muscles under atrophy-inducing conditions, such as obesity [61], was significantly decreased by 61% and 59% with mid- (p = 0.0424) and high-dose (p = 0.0415) GB administration, respectively, compared to the H group (Figure 6H).